NCT05335993 - A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

March 30, 2025

Study Completion Date

July 30, 2025

Conditions

Recurrent Ovarian CancerRecurrent Epithelial Cancer of OvaryRecurrent Epithelial Ovarian CancerRecurrent Fallopian Tube CancerPeritoneal CancerRecurrent Carcinoma of OvaryAdenocarcinoma of Ovary

Interventions

BIOLOGICAL

Oregovomab

2 mg, added to 50 mL of Sodium Chloride infused over 20 ± 5 minutes.

DRUG

Niraparib

300mg administered orally once daily starting at the first day of treatment (Day 1 Week 1) to the end of Week 12. Subjects whose baseline weight is \<77 kg or platelet count is \<150,000 μL, the daily dosing will be 200mg.

Trial Locations (3)

22903

University of Virginia Health System, Charlottesville

27710

Duke Cancer Center, Durham

73104

Stephenson Cancer Center- University of Oklahoma Health Sciences Center, Oklahoma City